New evidence-based non-statin treatment to lower LDL-c and CV risk - PACE-CME

New evidencebased nonstatin treatment to lower LDLc and CV risk

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Do personalized reminders to clinicians result in higher use of high-intensity statins?
Do personalized reminders to clinicians result in higher use of high-intensity statins?
ACC.23
Do personalized reminders to clinicians result in higher use of high-intensity statins?
- Prof. Salim Virani, MD, PhD
Interesting developments in the field of PCSK9 inhibition
Interesting developments in the field of PCSK9 inhibition
ACC.23
Interesting developments in the field of PCSK9 inhibition
- Deepak Bhatt, MD
Implementing precision health for public health using causal AI
Implementing precision health for public health using causal AI
ACC.23
Implementing precision health for public health using causal AI
- Ami Bhatt, MD
Findings of a phase 2 trial with aldosteron synthase inhibitor in hypertension
Findings of a phase 2 trial with aldosteron synthase inhibitor in hypertension
ACC.23
Findings of a phase 2 trial with aldosteron synthase inhibitor in hypertension
- Deepak Bhatt, MD